InflaRx IFRX
NASDAQ IFRX
$2.10 +0.08 (+3.96%)
At close: Aug 21, 2026 · 4:00 PM EDT

InflaRx (IFRX) Change in Accured Expenses (2019 - 2026)

InflaRx (IFRX) posted Change in Accured Expenses of $33932.9 for Q1 2026, up 68.01% sequentially from $20197.3 in Q4 2025, and down 30.32% YoY from $48697.0 in Q1 2025.

InflaRx (IFRX) Change in Accured Expenses (2019 - 2026) Analysis & Trends

InflaRx has reported Change in Accured Expenses for 8 years, with the latest figure at $33932.9 in Q1 2026.

  • Quarterly Change in Accured Expenses fell 30.32% year-over-year to $33932.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46329.1 (up 101.65% YoY) and the FY2025 annual result came in at $64862.5, up 102.32% from the prior year.
  • Change in Accured Expenses advanced to $33932.9 in Q1 2026 per IFRX's latest filing, from $20197.3 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $3.1 million in Q3 2023 and troughed at -$3.0 million in Q2 2024.
  • A 5-year average of $17920.1 and a median of $17158.4 in 2023 frame the typical range for Change in Accured Expenses.
  • The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 23555.74% in 2023, then slumped 6270.46% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $4429.9 in 2022, then sank by 3871.86% to -$167090.2 in 2023, then jumped by 141.74% to $69736.5 in 2024, then slumped by 71.04% to $20197.3 in 2025, then jumped by 68.01% to $33932.9 in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered $33932.9, $20197.3, and -$23391.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 InflaRx 140.30 Mn -43.96 Mn 2.74 Bn -18,206.07

Historic Data

Download Data
DateValue
Mar 31, 2026 33,932.89
Mar 31, 2026 33,932.89
Dec 31, 2025 20,197.32
Dec 31, 2025 20,197.32
Sep 30, 2025 -23,391.62
Sep 30, 2025 -23,391.62
Jun 30, 2025 15,590.48
Jun 30, 2025 15,590.48
Mar 31, 2025 48,696.99
Mar 31, 2025 48,696.99
Dec 31, 2024 69,736.54
Dec 31, 2024 69,736.54
Sep 30, 2024 68,044.58
Sep 30, 2024 68,044.58
Jun 30, 2024 -2.99 Mn
Jun 30, 2024 -2.99 Mn
Mar 31, 2024 67,807.44
Mar 31, 2024 67,807.44
Dec 31, 2023 -167,090.24
Dec 31, 2023 -167,090.24